RPL3 and cancer: These data imply that there is a mechanistic link between the response pathway to drug-induced ribosomal stress and the development of drug resistance and suggest the possibility of targeting uL3 to modulate the redox status of cancer cells for future therapeutic purposes in order to overcome MDR.